176 related articles for article (PubMed ID: 16920540)
1. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART).
Lin AL; Johnson DA; Sims CA; Stephan KT; Yeh CK
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):318-24. PubMed ID: 16920540
[TBL] [Abstract][Full Text] [Related]
2. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
[TBL] [Abstract][Full Text] [Related]
3. Oral Candida colonization and its relation with predisposing factors in HIV-infected children and their uninfected siblings in Brazil: the era of highly active antiretroviral therapy.
Cerqueira DF; Portela MB; Pomarico L; de Araújo Soares RM; de Souza IP; Castro GF
J Oral Pathol Med; 2010 Feb; 39(2):188-94. PubMed ID: 20040023
[TBL] [Abstract][Full Text] [Related]
4. Salivary secretion, mucin concentrations and Candida carriage in HIV-infected patients.
Jainkittivong A; Lin AL; Johnson DA; Langlais RP; Yeh CK
Oral Dis; 2009 Apr; 15(3):229-34. PubMed ID: 19207880
[TBL] [Abstract][Full Text] [Related]
5. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants.
Navazesh M; Mulligan R; Barrón Y; Redford M; Greenspan D; Alves M; Phelan J;
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jun; 95(6):693-8. PubMed ID: 12789150
[TBL] [Abstract][Full Text] [Related]
6. HIV infection, as opposed to antiretroviral therapy, does not cause changes in the concentration levels of specific salivary electrolytes.
Biocina-Lukenda D; Blazić-Potocki Z; Lukenda J; Potocki-Karacić T
Coll Antropol; 2009 Mar; 33(1):93-7. PubMed ID: 19408610
[TBL] [Abstract][Full Text] [Related]
7. Alteration in salivary function in early HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Dent Res; 2003 Sep; 82(9):719-24. PubMed ID: 12939357
[TBL] [Abstract][Full Text] [Related]
8. Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy.
Palios J; Ikonomidis I; Lekakis J; Tsiodras S; Poulakou G; Antoniadou A; Panagopoulos P; Papadopoulos A; Giamarellou H; Anastasiou-Nana M; Kremastinos D
Microcirculation; 2010 May; 17(4):303-10. PubMed ID: 20536743
[TBL] [Abstract][Full Text] [Related]
9. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
10. Salivary anticandidal activity and saliva composition in an HIV-infected cohort.
Lin AL; Johnson DA; Patterson TF; Wu Y; Lu DL; Shi Q; Yeh CK
Oral Microbiol Immunol; 2001 Oct; 16(5):270-8. PubMed ID: 11555303
[TBL] [Abstract][Full Text] [Related]
11. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
[TBL] [Abstract][Full Text] [Related]
12. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
13. Periodontal conditions and distribution of Prevotella intermedia, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans in HIV-infected patients undergoing anti-retroviral therapy and in an HIV-seronegative group of the Venezuelan population.
Brito A; Escalona LA; Correnti M; Perrone M; Bravo IM; Tovar V
Acta Odontol Latinoam; 2008; 21(1):89-96. PubMed ID: 18841752
[TBL] [Abstract][Full Text] [Related]
14. Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era.
Nittayananta W; Chanowanna N; Jealae S; Nauntofte B; Stoltze K
J Oral Pathol Med; 2010 Jan; 39(1):28-34. PubMed ID: 19709350
[TBL] [Abstract][Full Text] [Related]
15. A comparison of salivary calprotectin levels in subjects with and without oral candidiasis.
Kleinegger CL; Stoeckel DC; Kurago ZB
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Jul; 92(1):62-7. PubMed ID: 11458247
[TBL] [Abstract][Full Text] [Related]
16. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
Manfredi R; Calza L; Chiodo F
J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
[TBL] [Abstract][Full Text] [Related]
17. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
18. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
19. Salivary lactoferrin in HIV-infected children: correlation with Candida albicans carriage, oral manifestations, HIV infection and its antifungal activity.
Alves TP; Simões AC; Soares RM; Moreno DS; Portela MB; Castro GF
Arch Oral Biol; 2014 Aug; 59(8):775-82. PubMed ID: 24837476
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
